ClinicalTrialsFinder
RecruitingPhase 4NCT05858632

Immune Spatial Features of Guselkumab Cutaneous Response

Sponsor

University of California, San Francisco

Enrollment

10 participants

Start Date

Jul 1, 2023

Study Type

INTERVENTIONAL

Conditions

Psoriasis of Scalp

Summary

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Eligibility

Min Age: 18 Years

Exclusion Criteria9

  • taking systemic immunosuppressives in the last 4 weeks
  • pregnancy
  • severe immunodeficiency (either from genetic or infectious causes).
  • tuberculosis or other active serious infection
  • active systemic malignancy.
  • breast-feeding
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • Males who are trying to conceive
  • \-

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGuselkumab

Guselkumab treatment for \~ 9 months

Locations(1)

University of California San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05858632